LABORATORY REFERENCE
Reconstitution and dilution reference
Every compound in the catalogue, with the solvent it is handled in, the concentration each diluent volume produces, storage for both forms, and what the published stability evidence does and does not cover. This is laboratory dilution: mass, volume and concentration. It contains no dose, no per-use amount and no route of administration.
49 compounds · 4 solvents · updated 2 November 2026 · open the calculator
The solvents
Bacteriostatic water
Sterile water with 0.9% benzyl alcohol
The default solvent for a lyophilised vial that will be opened more than once. Benzyl alcohol at 0.9% is bacteriostatic, which limits microbial growth in a multi-access vial (Meyer 2007). It does not stabilise the peptide chemically.
Benzyl alcohol absorbs in the ultraviolet around 257 nm, so it is the wrong solvent for any spectrophotometric measurement at or near 260 nm, and it is not used where a preservative would interfere with an assay.
Sterile water, no preservative
Water for laboratory use, sterile, without a preservative
Used where a preservative would interfere with the measurement or the chemistry, and where the preparation is a single-use stock rather than a multi-access vial. Plain water supports microbial growth, so a sterile-water stock is prepared fresh and either used the same day or aliquoted and frozen.
No antimicrobial protection at all. One access, one aliquot, and no return to the vial days later.
Dilute acetic acid, 0.1 M
0.1 mol/l acetic acid in sterile water, filtered
Some peptides are poorly soluble at neutral pH and are handled as an acidic stock; the stock is then diluted into the assay buffer on the day (Wang 1999).
Acidic stocks are not neutralised before storage. Prepare 0.1 M acetic acid by dilution of glacial acetic acid in sterile water, filter it, and record the preparation date on the label.
Dimethyl sulfoxide, anhydrous
Anhydrous dimethyl sulfoxide, 99.9% or better
Used only where the material will not reach a workable concentration in water. The powder is pre-dissolved in the minimum volume of DMSO and an aliquot of that concentrate is diluted into aqueous buffer. No aqueous stock is claimed, and none of the water-only arithmetic applies.
DMSO is not interchangeable with water. It freezes at about 18.5°C, so it crystallises if it is stored cold; it is hygroscopic, so keep the bottle sealed; and it carries solutes through many plastics, so use glass or polypropylene. Record the final DMSO percentage, because a co-solvent changes the behaviour of most assays.
Metabolic research
Retatrutide10mg, 20mg, 30mgBacteriostatic water10 mg/ml at 1 ml
Solvent
No compound-specific solvent or solubility data is published for this material. Bacteriostatic water is the default for a lyophilised preparation.
Concentration options
10mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 1 ml | 10 mg/ml | 10,000 |
| 2 ml | 5 mg/ml | 5,000 |
| 2.5 ml | 4 mg/ml | 4,000 |
| 5 ml | 2 mg/ml | 2,000 |
20mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 2 ml | 10 mg/ml | 10,000 |
| 5 ml | 4 mg/ml | 4,000 |
30mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 3 ml | 10 mg/ml | 10,000 |
| 5 ml | 6 mg/ml | 6,000 |
Volumes are concentration options, not a protocol. Do not exceed the nominal capacity of the vial.
Lyophilised storage
Sealed vial: -20°C for long-term storage, 2 to 8°C for up to a few months. Keep it dark and dry and let the vial reach room temperature before opening, so moisture does not condense on the powder.
Diluted storage
2 to 8°C, protected from light. If the preparation has to be kept longer, divide it into single-use aliquots and freeze them at -20°C, then thaw each aliquot once.
Stability data
No published stability data for this compound in either form. Store it as set out above and treat any time in solution as short.
Handling cautions
- Wipe the stopper with a 70% alcohol wipe and let it dry before every access, and work on a clean, low-draught surface.
- Run the diluent down the inside wall of the vial rather than onto the powder, then swirl or roll; do not vortex or shake, because foaming and shear promote aggregation (Manning 2010).
Sources
- Catalogue specification for Retatrutide, held in the product data for this site.
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 2010. PMID 20143256
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 1999. PMID 10460913
- Meyer BK, Ni A, Hu B, Shi L. Antimicrobial preservative use in parenteral products: past and present. Journal of Pharmaceutical Sciences, 2007. PMID 17722087
Tirzepatide10mg, 20mg, 30mg, 40mg, 60mgBacteriostatic water10 mg/ml at 1 ml
Solvent
No compound-specific solvent or solubility data is published for this material. Bacteriostatic water is the default for a lyophilised preparation.
Concentration options
10mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 1 ml | 10 mg/ml | 10,000 |
| 2 ml | 5 mg/ml | 5,000 |
| 2.5 ml | 4 mg/ml | 4,000 |
| 5 ml | 2 mg/ml | 2,000 |
20mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 2 ml | 10 mg/ml | 10,000 |
| 5 ml | 4 mg/ml | 4,000 |
30mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 3 ml | 10 mg/ml | 10,000 |
| 5 ml | 6 mg/ml | 6,000 |
40mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 4 ml | 10 mg/ml | 10,000 |
| 5 ml | 8 mg/ml | 8,000 |
| 10 ml | 4 mg/ml | 4,000 |
60mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 5 ml | 12 mg/ml | 12,000 |
| 10 ml | 6 mg/ml | 6,000 |
Volumes are concentration options, not a protocol. Do not exceed the nominal capacity of the vial.
Lyophilised storage
Sealed vial: -20°C for long-term storage, 2 to 8°C for up to a few months. Keep it dark and dry and let the vial reach room temperature before opening, so moisture does not condense on the powder.
Diluted storage
2 to 8°C, protected from light. If the preparation has to be kept longer, divide it into single-use aliquots and freeze them at -20°C, then thaw each aliquot once.
Stability data
Acid hydrolysis, base hydrolysis, oxidation and photolysis are the documented degradation routes in aqueous solution, and a stability-indicating HPLC method separates each stress condition from the intact peak. (Khalil 2026, BMC Chemistry, PMID 41588418)
Handling cautions
- Wipe the stopper with a 70% alcohol wipe and let it dry before every access, and work on a clean, low-draught surface.
- Run the diluent down the inside wall of the vial rather than onto the powder, then swirl or roll; do not vortex or shake, because foaming and shear promote aggregation (Manning 2010).
Sources
- Catalogue specification for Tirzepatide, held in the product data for this site.
- Khalil 2026, BMC Chemistry, PMID 41588418
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 2010. PMID 20143256
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 1999. PMID 10460913
- Meyer BK, Ni A, Hu B, Shi L. Antimicrobial preservative use in parenteral products: past and present. Journal of Pharmaceutical Sciences, 2007. PMID 17722087
Semaglutide10mg, 20mg, 30mgBacteriostatic water10 mg/ml at 1 ml
Solvent
No compound-specific solvent or solubility data is published for this material. Bacteriostatic water is the default for a lyophilised preparation.
Concentration options
10mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 1 ml | 10 mg/ml | 10,000 |
| 2 ml | 5 mg/ml | 5,000 |
| 2.5 ml | 4 mg/ml | 4,000 |
| 5 ml | 2 mg/ml | 2,000 |
20mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 2 ml | 10 mg/ml | 10,000 |
| 5 ml | 4 mg/ml | 4,000 |
30mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 3 ml | 10 mg/ml | 10,000 |
| 5 ml | 6 mg/ml | 6,000 |
Volumes are concentration options, not a protocol. Do not exceed the nominal capacity of the vial.
Lyophilised storage
Sealed vial: -20°C for long-term storage, 2 to 8°C for up to a few months. Keep it dark and dry and let the vial reach room temperature before opening, so moisture does not condense on the powder.
Diluted storage
2 to 8°C, protected from light. If the preparation has to be kept longer, divide it into single-use aliquots and freeze them at -20°C, then thaw each aliquot once.
Stability data
Degradation is fastest between pH 4.5 and 5.5, around the peptide's isoelectric point, and falls away as the pH moves above 7. (Malgave 2025, Journal of Peptide Science, PMID 40635175)
Handling cautions
- Wipe the stopper with a 70% alcohol wipe and let it dry before every access, and work on a clean, low-draught surface.
- Run the diluent down the inside wall of the vial rather than onto the powder, then swirl or roll; do not vortex or shake, because foaming and shear promote aggregation (Manning 2010).
Sources
- Catalogue specification for Semaglutide, held in the product data for this site.
- Malgave 2025, Journal of Peptide Science, PMID 40635175
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 2010. PMID 20143256
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 1999. PMID 10460913
- Meyer BK, Ni A, Hu B, Shi L. Antimicrobial preservative use in parenteral products: past and present. Journal of Pharmaceutical Sciences, 2007. PMID 17722087
AOD-96045mg, 10mgBacteriostatic water5 mg/ml at 1 ml
Solvent
No compound-specific solvent or solubility data is published for this material. Bacteriostatic water is the default for a lyophilised preparation.
Concentration options
5mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 1 ml | 5 mg/ml | 5,000 |
| 2 ml | 2.5 mg/ml | 2,500 |
| 2.5 ml | 2 mg/ml | 2,000 |
10mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 1 ml | 10 mg/ml | 10,000 |
| 2 ml | 5 mg/ml | 5,000 |
| 2.5 ml | 4 mg/ml | 4,000 |
| 5 ml | 2 mg/ml | 2,000 |
Volumes are concentration options, not a protocol. Do not exceed the nominal capacity of the vial.
Lyophilised storage
Sealed vial: -20°C for long-term storage, 2 to 8°C for up to a few months. Keep it dark and dry and let the vial reach room temperature before opening, so moisture does not condense on the powder.
Diluted storage
2 to 8°C, protected from light. If the preparation has to be kept longer, divide it into single-use aliquots and freeze them at -20°C, then thaw each aliquot once.
Stability data
No published stability data for this compound in either form. Store it as set out above and treat any time in solution as short.
Handling cautions
- Wipe the stopper with a 70% alcohol wipe and let it dry before every access, and work on a clean, low-draught surface.
- Run the diluent down the inside wall of the vial rather than onto the powder, then swirl or roll; do not vortex or shake, because foaming and shear promote aggregation (Manning 2010).
Sources
- Catalogue specification for AOD-9604, held in the product data for this site.
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 2010. PMID 20143256
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 1999. PMID 10460913
- Meyer BK, Ni A, Hu B, Shi L. Antimicrobial preservative use in parenteral products: past and present. Journal of Pharmaceutical Sciences, 2007. PMID 17722087
5-Amino-1MQ50mg, 10mgBacteriostatic water10 mg/ml at 5 ml
Solvent
Catalogue specification: red-brown to dark brown iodide salt. No compound-specific solvent or solubility data is published; bacteriostatic water is the default for a small-molecule laboratory standard.
Concentration options
50mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 5 ml | 10 mg/ml | 10,000 |
| 10 ml | 5 mg/ml | 5,000 |
10mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 1 ml | 10 mg/ml | 10,000 |
| 2 ml | 5 mg/ml | 5,000 |
| 2.5 ml | 4 mg/ml | 4,000 |
| 5 ml | 2 mg/ml | 2,000 |
Volumes are concentration options, not a protocol. Do not exceed the nominal capacity of the vial.
Lyophilised storage
Sealed vial: -20°C for long-term storage, 2 to 8°C for up to a few months. Keep it dark and dry and let the vial reach room temperature before opening, so moisture does not condense on the powder.
Diluted storage
2 to 8°C, protected from light. If the preparation has to be kept longer, divide it into single-use aliquots and freeze them at -20°C, then thaw each aliquot once.
Stability data
No published stability data for this compound in either form. Store it as set out above and treat any time in solution as short.
Handling cautions
- Keep the solid away from strong oxidisers, which can liberate iodine from the iodide salt.
- Wipe the stopper with a 70% alcohol wipe and let it dry before every access, and work on a clean, low-draught surface.
- Run the diluent down the inside wall of the vial rather than onto the powder, then swirl or roll; do not vortex or shake, because foaming and shear promote aggregation (Manning 2010).
Sources
- Catalogue specification for 5-Amino-1MQ (powder (iodide salt); red-brown to dark brown solid), held in the product data for this site.
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 2010. PMID 20143256
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 1999. PMID 10460913
- Meyer BK, Ni A, Hu B, Shi L. Antimicrobial preservative use in parenteral products: past and present. Journal of Pharmaceutical Sciences, 2007. PMID 17722087
MOTS-c10mg, 40mgBacteriostatic water10 mg/ml at 1 ml
Solvent
No compound-specific solvent or solubility data is published for this material. Bacteriostatic water is the default for a lyophilised preparation.
Concentration options
10mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 1 ml | 10 mg/ml | 10,000 |
| 2 ml | 5 mg/ml | 5,000 |
| 2.5 ml | 4 mg/ml | 4,000 |
| 5 ml | 2 mg/ml | 2,000 |
40mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 4 ml | 10 mg/ml | 10,000 |
| 5 ml | 8 mg/ml | 8,000 |
| 10 ml | 4 mg/ml | 4,000 |
Volumes are concentration options, not a protocol. Do not exceed the nominal capacity of the vial.
Lyophilised storage
Sealed vial: -20°C for long-term storage, 2 to 8°C for up to a few months. Keep it dark and dry and let the vial reach room temperature before opening, so moisture does not condense on the powder.
Diluted storage
2 to 8°C, protected from light. If the preparation has to be kept longer, divide it into single-use aliquots and freeze them at -20°C, then thaw each aliquot once.
Stability data
No published stability data for this compound in either form. Store it as set out above and treat any time in solution as short.
Handling cautions
- Wipe the stopper with a 70% alcohol wipe and let it dry before every access, and work on a clean, low-draught surface.
- Run the diluent down the inside wall of the vial rather than onto the powder, then swirl or roll; do not vortex or shake, because foaming and shear promote aggregation (Manning 2010).
- The sequence contains methionine, the usual first site of oxidation; keep the solution cold, dark and with minimal headspace (Manning 2010).
- The sequence contains tryptophan, which photo-oxidises; keep the vial in its box or an opaque container (Manning 2010).
Sources
- Catalogue specification for MOTS-c, held in the product data for this site.
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 2010. PMID 20143256
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 1999. PMID 10460913
- Meyer BK, Ni A, Hu B, Shi L. Antimicrobial preservative use in parenteral products: past and present. Journal of Pharmaceutical Sciences, 2007. PMID 17722087
HGH Fragment 176-1915mgBacteriostatic water5 mg/ml at 1 ml
Solvent
No compound-specific solvent or solubility data is published for this material. Bacteriostatic water is the default for a lyophilised preparation.
Concentration options
5mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 1 ml | 5 mg/ml | 5,000 |
| 2 ml | 2.5 mg/ml | 2,500 |
| 2.5 ml | 2 mg/ml | 2,000 |
Volumes are concentration options, not a protocol. Do not exceed the nominal capacity of the vial.
Lyophilised storage
Sealed vial: -20°C for long-term storage, 2 to 8°C for up to a few months. Keep it dark and dry and let the vial reach room temperature before opening, so moisture does not condense on the powder.
Diluted storage
2 to 8°C, protected from light. If the preparation has to be kept longer, divide it into single-use aliquots and freeze them at -20°C, then thaw each aliquot once.
Stability data
No published stability data for this compound in either form. Store it as set out above and treat any time in solution as short.
Handling cautions
- Wipe the stopper with a 70% alcohol wipe and let it dry before every access, and work on a clean, low-draught surface.
- Run the diluent down the inside wall of the vial rather than onto the powder, then swirl or roll; do not vortex or shake, because foaming and shear promote aggregation (Manning 2010).
Sources
- Catalogue specification for HGH Fragment 176-191, held in the product data for this site.
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 2010. PMID 20143256
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 1999. PMID 10460913
- Meyer BK, Ni A, Hu B, Shi L. Antimicrobial preservative use in parenteral products: past and present. Journal of Pharmaceutical Sciences, 2007. PMID 17722087
L-Carnitine600mg/ml, 10mlBacteriostatic watersolution, no dilution step
Solvent
Supplied as a solution at 600 mg/ml in a 10 ml vial, so there is nothing to reconstitute. Concentration arithmetic for a solution works the other way: volume = mass / concentration.
Concentration options
Supplied as a solution, so there is no reconstitution step. Concentration is printed on the label; to find the volume that contains a mass, divide the mass by the stated concentration.
Lyophilised storage
Sealed vial: -20°C for long-term storage, 2 to 8°C for up to a few months. Keep it dark and dry and let the vial reach room temperature before opening, so moisture does not condense on the powder.
Diluted storage
2 to 8°C, protected from light. If the preparation has to be kept longer, divide it into single-use aliquots and freeze them at -20°C, then thaw each aliquot once.
Stability data
Degradation of L-carnitine in aqueous solution is thermal and follows Arrhenius kinetics, so temperature and time in solution, not pH, set the working window. This is a food-matrix kinetics study rather than a sterile-product study, so it describes the shape of the risk rather than a shelf life. (Goula 2018, Journal of Food Engineering, doi:10.1016/j.jfoodeng.2018.03.011)
Handling cautions
Sources
- Catalogue specification for L-Carnitine (solution; 600mg/ml, 10ml; solution), held in the product data for this site.
- Goula 2018, Journal of Food Engineering, doi:10.1016/j.jfoodeng.2018.03.011
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 2010. PMID 20143256
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 1999. PMID 10460913
- Meyer BK, Ni A, Hu B, Shi L. Antimicrobial preservative use in parenteral products: past and present. Journal of Pharmaceutical Sciences, 2007. PMID 17722087
Regenerative research
BPC-1575mg, 10mgBacteriostatic water5 mg/ml at 1 ml
Solvent
No compound-specific solvent or solubility data is published for this material. Bacteriostatic water is the default for a lyophilised preparation.
Concentration options
5mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 1 ml | 5 mg/ml | 5,000 |
| 2 ml | 2.5 mg/ml | 2,500 |
| 2.5 ml | 2 mg/ml | 2,000 |
10mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 1 ml | 10 mg/ml | 10,000 |
| 2 ml | 5 mg/ml | 5,000 |
| 2.5 ml | 4 mg/ml | 4,000 |
| 5 ml | 2 mg/ml | 2,000 |
Volumes are concentration options, not a protocol. Do not exceed the nominal capacity of the vial.
Lyophilised storage
Sealed vial: -20°C for long-term storage, 2 to 8°C for up to a few months. Keep it dark and dry and let the vial reach room temperature before opening, so moisture does not condense on the powder.
Diluted storage
2 to 8°C, protected from light. If the preparation has to be kept longer, divide it into single-use aliquots and freeze them at -20°C, then thaw each aliquot once.
Stability data
No published stability data for this compound in either form. Store it as set out above and treat any time in solution as short.
Handling cautions
- Wipe the stopper with a 70% alcohol wipe and let it dry before every access, and work on a clean, low-draught surface.
- Run the diluent down the inside wall of the vial rather than onto the powder, then swirl or roll; do not vortex or shake, because foaming and shear promote aggregation (Manning 2010).
Sources
- Catalogue specification for BPC-157, held in the product data for this site.
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 2010. PMID 20143256
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 1999. PMID 10460913
- Meyer BK, Ni A, Hu B, Shi L. Antimicrobial preservative use in parenteral products: past and present. Journal of Pharmaceutical Sciences, 2007. PMID 17722087
TB-5005mg, 10mgBacteriostatic water5 mg/ml at 1 ml
Solvent
No compound-specific solvent or solubility data is published for this material. Bacteriostatic water is the default for a lyophilised preparation.
Concentration options
5mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 1 ml | 5 mg/ml | 5,000 |
| 2 ml | 2.5 mg/ml | 2,500 |
| 2.5 ml | 2 mg/ml | 2,000 |
10mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 1 ml | 10 mg/ml | 10,000 |
| 2 ml | 5 mg/ml | 5,000 |
| 2.5 ml | 4 mg/ml | 4,000 |
| 5 ml | 2 mg/ml | 2,000 |
Volumes are concentration options, not a protocol. Do not exceed the nominal capacity of the vial.
Lyophilised storage
Sealed vial: -20°C for long-term storage, 2 to 8°C for up to a few months. Keep it dark and dry and let the vial reach room temperature before opening, so moisture does not condense on the powder.
Diluted storage
2 to 8°C, protected from light. If the preparation has to be kept longer, divide it into single-use aliquots and freeze them at -20°C, then thaw each aliquot once.
Stability data
No published stability data for this compound in either form. Store it as set out above and treat any time in solution as short.
Handling cautions
- Wipe the stopper with a 70% alcohol wipe and let it dry before every access, and work on a clean, low-draught surface.
- Run the diluent down the inside wall of the vial rather than onto the powder, then swirl or roll; do not vortex or shake, because foaming and shear promote aggregation (Manning 2010).
Sources
- Catalogue specification for TB-500, held in the product data for this site.
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 2010. PMID 20143256
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 1999. PMID 10460913
- Meyer BK, Ni A, Hu B, Shi L. Antimicrobial preservative use in parenteral products: past and present. Journal of Pharmaceutical Sciences, 2007. PMID 17722087
GHK-Cu50mg, 100mgBacteriostatic water10 mg/ml at 5 ml
Solvent
The copper-peptide complex is water-soluble and gives a characteristic blue solution; the colour is the complex, not degradation.
Concentration options
50mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 5 ml | 10 mg/ml | 10,000 |
| 10 ml | 5 mg/ml | 5,000 |
100mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 5 ml | 20 mg/ml | 20,000 |
| 10 ml | 10 mg/ml | 10,000 |
Volumes are concentration options, not a protocol. Do not exceed the nominal capacity of the vial.
Lyophilised storage
Sealed vial: -20°C for long-term storage, 2 to 8°C for up to a few months. Keep it dark and dry and let the vial reach room temperature before opening, so moisture does not condense on the powder.
Diluted storage
2 to 8°C, protected from light. If the preparation has to be kept longer, divide it into single-use aliquots and freeze them at -20°C, then thaw each aliquot once.
Stability data
GHK-Cu held its integrity in water and in pH 4.5 to 7.4 buffers for at least two weeks at 60 degrees. Hydrolysis appeared only under basic and oxidative stress, and a stability-indicating HPLC method separated the degradants from the intact complex. (Badenhorst 2016, Pharmaceutical Development and Technology, PMID 25384620)
Handling cautions
- A blue solution is expected. Do not read colour as a fault, and do not add a chelator such as EDTA to the stock, which strips the copper.
- Record the appearance at reconstitution so a later colour change can be judged against it.
- Wipe the stopper with a 70% alcohol wipe and let it dry before every access, and work on a clean, low-draught surface.
- Run the diluent down the inside wall of the vial rather than onto the powder, then swirl or roll; do not vortex or shake, because foaming and shear promote aggregation (Manning 2010).
Sources
- Catalogue specification for GHK-Cu (blue lyophilised powder), held in the product data for this site.
- Badenhorst 2016, Pharmaceutical Development and Technology, PMID 25384620 (preformulation study of the GHK-Cu complex itself: stable in water and pH 4.5 to 7.4 buffers for at least two weeks at 60 degrees, first-order hydrolysis only under basic and oxidative stress)
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 2010. PMID 20143256
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 1999. PMID 10460913
- Meyer BK, Ni A, Hu B, Shi L. Antimicrobial preservative use in parenteral products: past and present. Journal of Pharmaceutical Sciences, 2007. PMID 17722087
KPV10mgBacteriostatic water10 mg/ml at 1 ml
Solvent
No compound-specific solvent or solubility data is published for this material. Bacteriostatic water is the default for a lyophilised preparation.
Concentration options
10mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 1 ml | 10 mg/ml | 10,000 |
| 2 ml | 5 mg/ml | 5,000 |
| 2.5 ml | 4 mg/ml | 4,000 |
| 5 ml | 2 mg/ml | 2,000 |
Volumes are concentration options, not a protocol. Do not exceed the nominal capacity of the vial.
Lyophilised storage
Sealed vial: -20°C for long-term storage, 2 to 8°C for up to a few months. Keep it dark and dry and let the vial reach room temperature before opening, so moisture does not condense on the powder.
Diluted storage
2 to 8°C, protected from light. If the preparation has to be kept longer, divide it into single-use aliquots and freeze them at -20°C, then thaw each aliquot once.
Stability data
Under acid, alkali and peroxide stress KPV yields lys-pro-diketopiperazine as its main degradation product, so the cyclisation route is the one to design around. (Pawar 2015, Biomedical Chromatography, PMID 25298219)
Handling cautions
- Wipe the stopper with a 70% alcohol wipe and let it dry before every access, and work on a clean, low-draught surface.
- Run the diluent down the inside wall of the vial rather than onto the powder, then swirl or roll; do not vortex or shake, because foaming and shear promote aggregation (Manning 2010).
Sources
- Catalogue specification for KPV, held in the product data for this site.
- Pawar 2015, Biomedical Chromatography, PMID 25298219
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 2010. PMID 20143256
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 1999. PMID 10460913
- Meyer BK, Ni A, Hu B, Shi L. Antimicrobial preservative use in parenteral products: past and present. Journal of Pharmaceutical Sciences, 2007. PMID 17722087
LL-375mgBacteriostatic water5 mg/ml at 1 ml
Solvent
Water-soluble, but cationic and amphipathic: it foams and self-associates readily, so it is handled gently rather than jetted or vortexed.
Concentration options
5mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 1 ml | 5 mg/ml | 5,000 |
| 2 ml | 2.5 mg/ml | 2,500 |
| 2.5 ml | 2 mg/ml | 2,000 |
Volumes are concentration options, not a protocol. Do not exceed the nominal capacity of the vial.
Lyophilised storage
Sealed vial: -20°C for long-term storage, 2 to 8°C for up to a few months. Keep it dark and dry and let the vial reach room temperature before opening, so moisture does not condense on the powder.
Diluted storage
2 to 8°C, protected from light. If the preparation has to be kept longer, divide it into single-use aliquots and freeze them at -20°C, then thaw each aliquot once.
Stability data
No published shelf-life figure for this compound in aqueous solution. The research that does exist is printed below, labelled with how far it actually applies, and none of it is used here as a working time in solution: store it as set out above and treat any time in solution as short.
Same molecule, non-aqueous matrix: LL-37 is degraded by serine proteases in wound fluid within hours while a matrix metalloproteinase leaves it alone. That is enzymatic loss in a biological matrix, not an aqueous pH-rate dataset, so it is not used here as a solution shelf life. (Gronberg 2011, Acta Dermato-Venereologica, PMID 21547341)
Handling cautions
- Do not vortex or shake: this peptide foams and aggregates at the air-water interface (Manning 2010).
- In low-ionic-strength water it self-associates; if the assay needs a defined ionic strength, record the buffer used.
- Wipe the stopper with a 70% alcohol wipe and let it dry before every access, and work on a clean, low-draught surface.
- Run the diluent down the inside wall of the vial rather than onto the powder, then swirl or roll; do not vortex or shake, because foaming and shear promote aggregation (Manning 2010).
Sources
- Catalogue specification for LL-37, held in the product data for this site.
- Gronberg 2011, Acta Dermato-Venereologica, PMID 21547341 (same molecule, non-aqueous matrix)
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 2010. PMID 20143256
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 1999. PMID 10460913
- Meyer BK, Ni A, Hu B, Shi L. Antimicrobial preservative use in parenteral products: past and present. Journal of Pharmaceutical Sciences, 2007. PMID 17722087
ARA-29010mgBacteriostatic water10 mg/ml at 1 ml
Solvent
No compound-specific solvent or solubility data is published for this material. Bacteriostatic water is the default for a lyophilised preparation.
Concentration options
10mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 1 ml | 10 mg/ml | 10,000 |
| 2 ml | 5 mg/ml | 5,000 |
| 2.5 ml | 4 mg/ml | 4,000 |
| 5 ml | 2 mg/ml | 2,000 |
Solubility is pH dependent and the alkaline end is the soluble one. No primary solubility dataset is on file, so do not assume a neutral-pH stock will clear at the concentrations in the table: test a small quantity first, adjust the pH, and record the pH used.
Volumes are concentration options, not a protocol. Do not exceed the nominal capacity of the vial.
Lyophilised storage
Sealed vial: -20°C for long-term storage, 2 to 8°C for up to a few months. Keep it dark and dry and let the vial reach room temperature before opening, so moisture does not condense on the powder.
Diluted storage
2 to 8°C, protected from light. If the preparation has to be kept longer, divide it into single-use aliquots and freeze them at -20°C, then thaw each aliquot once.
Stability data
No published stability data for this compound in either form. Store it as set out above and treat any time in solution as short.
Handling cautions
- Wipe the stopper with a 70% alcohol wipe and let it dry before every access, and work on a clean, low-draught surface.
- Run the diluent down the inside wall of the vial rather than onto the powder, then swirl or roll; do not vortex or shake, because foaming and shear promote aggregation (Manning 2010).
Sources
- Catalogue specification for ARA-290, held in the product data for this site.
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 2010. PMID 20143256
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 1999. PMID 10460913
- Meyer BK, Ni A, Hu B, Shi L. Antimicrobial preservative use in parenteral products: past and present. Journal of Pharmaceutical Sciences, 2007. PMID 17722087
SNAP-810mgBacteriostatic water10 mg/ml at 1 ml
Solvent
No compound-specific solvent or solubility data is published for this material. Bacteriostatic water is the default for a lyophilised preparation.
Concentration options
10mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 1 ml | 10 mg/ml | 10,000 |
| 2 ml | 5 mg/ml | 5,000 |
| 2.5 ml | 4 mg/ml | 4,000 |
| 5 ml | 2 mg/ml | 2,000 |
Volumes are concentration options, not a protocol. Do not exceed the nominal capacity of the vial.
Lyophilised storage
Sealed vial: -20°C for long-term storage, 2 to 8°C for up to a few months. Keep it dark and dry and let the vial reach room temperature before opening, so moisture does not condense on the powder.
Diluted storage
2 to 8°C, protected from light. If the preparation has to be kept longer, divide it into single-use aliquots and freeze them at -20°C, then thaw each aliquot once.
Stability data
SNAP-8 held its integrity for at least 96 hours in distilled water when refrigerated at 4 degrees. That is the documented bench life, and it is short. (Ji 2020, Journal of Analytical Science and Technology, doi:10.1186/s40543-020-00232-8)
Handling cautions
- Wipe the stopper with a 70% alcohol wipe and let it dry before every access, and work on a clean, low-draught surface.
- Run the diluent down the inside wall of the vial rather than onto the powder, then swirl or roll; do not vortex or shake, because foaming and shear promote aggregation (Manning 2010).
Sources
- Catalogue specification for SNAP-8, held in the product data for this site.
- Ji 2020, Journal of Analytical Science and Technology, doi:10.1186/s40543-020-00232-8
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 2010. PMID 20143256
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 1999. PMID 10460913
- Meyer BK, Ni A, Hu B, Shi L. Antimicrobial preservative use in parenteral products: past and present. Journal of Pharmaceutical Sciences, 2007. PMID 17722087
Growth hormone secretagogues
CJC-1295 no-DAC5mgBacteriostatic water or 0.1 M acetic acid5 mg/ml at 1 ml
Solvent
Salt form decides the solvent here. The acetate salt is the water-soluble one; the free base has limited water solubility and is handled in dilute acetic acid. The catalogue does not state which form a batch is, so the record shows both options and the batch record has to settle it.
Concentration options
5mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 1 ml | 5 mg/ml | 5,000 |
| 2 ml | 2.5 mg/ml | 2,500 |
| 2.5 ml | 2 mg/ml | 2,000 |
If the batch is the acetate salt, water is the solvent. If it is the free base, the stock is made in 0.1 M acetic acid. The catalogue does not state which form is in the vial, so confirm it from the batch record and record what was used.
Volumes are concentration options, not a protocol. Do not exceed the nominal capacity of the vial.
Lyophilised storage
Sealed vial: -20°C for long-term storage, 2 to 8°C for up to a few months. Keep it dark and dry and let the vial reach room temperature before opening, so moisture does not condense on the powder.
Diluted storage
2 to 8°C, protected from light. If the preparation has to be kept longer, divide it into single-use aliquots and freeze them at -20°C, then thaw each aliquot once.
Stability data
No published stability data for this compound in either form. Store it as set out above and treat any time in solution as short.
Handling cautions
- Wipe the stopper with a 70% alcohol wipe and let it dry before every access, and work on a clean, low-draught surface.
- Run the diluent down the inside wall of the vial rather than onto the powder, then swirl or roll; do not vortex or shake, because foaming and shear promote aggregation (Manning 2010).
Sources
- Catalogue specification for CJC-1295 no-DAC, held in the product data for this site.
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 2010. PMID 20143256
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 1999. PMID 10460913
- Meyer BK, Ni A, Hu B, Shi L. Antimicrobial preservative use in parenteral products: past and present. Journal of Pharmaceutical Sciences, 2007. PMID 17722087
CJC-1295 DAC5mgBacteriostatic water5 mg/ml at 1 ml
Solvent
No compound-specific solvent or solubility data is published for this material. Bacteriostatic water is the default for a lyophilised preparation.
Concentration options
5mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 1 ml | 5 mg/ml | 5,000 |
| 2 ml | 2.5 mg/ml | 2,500 |
| 2.5 ml | 2 mg/ml | 2,000 |
No primary solubility dataset is published for the DAC form. Supplier guidance puts the soluble range near 2 mg/ml, which is unverified, so start at the lower concentrations in the table and record what actually dissolved before making a more concentrated stock.
Volumes are concentration options, not a protocol. Do not exceed the nominal capacity of the vial.
Lyophilised storage
Sealed vial: -20°C for long-term storage, 2 to 8°C for up to a few months. Keep it dark and dry and let the vial reach room temperature before opening, so moisture does not condense on the powder.
Diluted storage
2 to 8°C, protected from light. If the preparation has to be kept longer, divide it into single-use aliquots and freeze them at -20°C, then thaw each aliquot once.
Stability data
No published stability data for this compound in either form. Store it as set out above and treat any time in solution as short.
Handling cautions
- Wipe the stopper with a 70% alcohol wipe and let it dry before every access, and work on a clean, low-draught surface.
- Run the diluent down the inside wall of the vial rather than onto the powder, then swirl or roll; do not vortex or shake, because foaming and shear promote aggregation (Manning 2010).
Sources
- Catalogue specification for CJC-1295 DAC, held in the product data for this site.
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 2010. PMID 20143256
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 1999. PMID 10460913
- Meyer BK, Ni A, Hu B, Shi L. Antimicrobial preservative use in parenteral products: past and present. Journal of Pharmaceutical Sciences, 2007. PMID 17722087
Ipamorelin5mg, 10mgBacteriostatic water5 mg/ml at 1 ml
Solvent
No compound-specific solvent or solubility data is published for this material. Bacteriostatic water is the default for a lyophilised preparation.
Concentration options
5mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 1 ml | 5 mg/ml | 5,000 |
| 2 ml | 2.5 mg/ml | 2,500 |
| 2.5 ml | 2 mg/ml | 2,000 |
10mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 1 ml | 10 mg/ml | 10,000 |
| 2 ml | 5 mg/ml | 5,000 |
| 2.5 ml | 4 mg/ml | 4,000 |
| 5 ml | 2 mg/ml | 2,000 |
Volumes are concentration options, not a protocol. Do not exceed the nominal capacity of the vial.
Lyophilised storage
Sealed vial: -20°C for long-term storage, 2 to 8°C for up to a few months. Keep it dark and dry and let the vial reach room temperature before opening, so moisture does not condense on the powder.
Diluted storage
2 to 8°C, protected from light. If the preparation has to be kept longer, divide it into single-use aliquots and freeze them at -20°C, then thaw each aliquot once.
Stability data
No published stability data for this compound in either form. Store it as set out above and treat any time in solution as short.
Handling cautions
- Wipe the stopper with a 70% alcohol wipe and let it dry before every access, and work on a clean, low-draught surface.
- Run the diluent down the inside wall of the vial rather than onto the powder, then swirl or roll; do not vortex or shake, because foaming and shear promote aggregation (Manning 2010).
Sources
- Catalogue specification for Ipamorelin, held in the product data for this site.
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 2010. PMID 20143256
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 1999. PMID 10460913
- Meyer BK, Ni A, Hu B, Shi L. Antimicrobial preservative use in parenteral products: past and present. Journal of Pharmaceutical Sciences, 2007. PMID 17722087
Tesamorelin5mg, 10mgBacteriostatic water5 mg/ml at 1 ml
Solvent
No compound-specific solvent or solubility data is published for this material. Bacteriostatic water is the default for a lyophilised preparation.
Concentration options
5mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 1 ml | 5 mg/ml | 5,000 |
| 2 ml | 2.5 mg/ml | 2,500 |
| 2.5 ml | 2 mg/ml | 2,000 |
10mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 1 ml | 10 mg/ml | 10,000 |
| 2 ml | 5 mg/ml | 5,000 |
| 2.5 ml | 4 mg/ml | 4,000 |
| 5 ml | 2 mg/ml | 2,000 |
Volumes are concentration options, not a protocol. Do not exceed the nominal capacity of the vial.
Lyophilised storage
Sealed vial: -20°C for long-term storage, 2 to 8°C for up to a few months. Keep it dark and dry and let the vial reach room temperature before opening, so moisture does not condense on the powder.
Diluted storage
2 to 8°C, protected from light. If the preparation has to be kept longer, divide it into single-use aliquots and freeze them at -20°C, then thaw each aliquot once.
Stability data
No published stability data for this compound in either form. Store it as set out above and treat any time in solution as short.
Handling cautions
- Wipe the stopper with a 70% alcohol wipe and let it dry before every access, and work on a clean, low-draught surface.
- Run the diluent down the inside wall of the vial rather than onto the powder, then swirl or roll; do not vortex or shake, because foaming and shear promote aggregation (Manning 2010).
Sources
- Catalogue specification for Tesamorelin, held in the product data for this site.
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 2010. PMID 20143256
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 1999. PMID 10460913
- Meyer BK, Ni A, Hu B, Shi L. Antimicrobial preservative use in parenteral products: past and present. Journal of Pharmaceutical Sciences, 2007. PMID 17722087
GHRP-25mg, 10mgBacteriostatic water5 mg/ml at 1 ml
Solvent
No compound-specific solvent or solubility data is published for this material. Bacteriostatic water is the default for a lyophilised preparation.
Concentration options
5mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 1 ml | 5 mg/ml | 5,000 |
| 2 ml | 2.5 mg/ml | 2,500 |
| 2.5 ml | 2 mg/ml | 2,000 |
10mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 1 ml | 10 mg/ml | 10,000 |
| 2 ml | 5 mg/ml | 5,000 |
| 2.5 ml | 4 mg/ml | 4,000 |
| 5 ml | 2 mg/ml | 2,000 |
Volumes are concentration options, not a protocol. Do not exceed the nominal capacity of the vial.
Lyophilised storage
Sealed vial: -20°C for long-term storage, 2 to 8°C for up to a few months. Keep it dark and dry and let the vial reach room temperature before opening, so moisture does not condense on the powder.
Diluted storage
2 to 8°C, protected from light. If the preparation has to be kept longer, divide it into single-use aliquots and freeze them at -20°C, then thaw each aliquot once.
Stability data
No published stability data for this compound in either form. Store it as set out above and treat any time in solution as short.
Handling cautions
- Wipe the stopper with a 70% alcohol wipe and let it dry before every access, and work on a clean, low-draught surface.
- Run the diluent down the inside wall of the vial rather than onto the powder, then swirl or roll; do not vortex or shake, because foaming and shear promote aggregation (Manning 2010).
- The sequence contains tryptophan, which photo-oxidises; keep the vial in its box or an opaque container (Manning 2010).
Sources
- Catalogue specification for GHRP-2, held in the product data for this site.
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 2010. PMID 20143256
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 1999. PMID 10460913
- Meyer BK, Ni A, Hu B, Shi L. Antimicrobial preservative use in parenteral products: past and present. Journal of Pharmaceutical Sciences, 2007. PMID 17722087
GHRP-65mg, 10mgBacteriostatic water5 mg/ml at 1 ml
Solvent
No compound-specific solvent or solubility data is published for this material. Bacteriostatic water is the default for a lyophilised preparation.
Concentration options
5mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 1 ml | 5 mg/ml | 5,000 |
| 2 ml | 2.5 mg/ml | 2,500 |
| 2.5 ml | 2 mg/ml | 2,000 |
10mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 1 ml | 10 mg/ml | 10,000 |
| 2 ml | 5 mg/ml | 5,000 |
| 2.5 ml | 4 mg/ml | 4,000 |
| 5 ml | 2 mg/ml | 2,000 |
Volumes are concentration options, not a protocol. Do not exceed the nominal capacity of the vial.
Lyophilised storage
Sealed vial: -20°C for long-term storage, 2 to 8°C for up to a few months. Keep it dark and dry and let the vial reach room temperature before opening, so moisture does not condense on the powder.
Diluted storage
2 to 8°C, protected from light. If the preparation has to be kept longer, divide it into single-use aliquots and freeze them at -20°C, then thaw each aliquot once.
Stability data
Heating GHRP-6 in the dark at 60 degrees across pH 3 to 8 produced a family of modified species: C-terminal deamidation peaked at pH 3 and 8, while hydrolysis and head-to-tail cyclisation were favoured between pH 6 and 7 in phosphate buffers. (Santana 2021, Journal of Pharmaceutical and Biomedical Analysis, PMID 33272786)
Handling cautions
- Avoid phosphate buffer and a working pH of 6 to 7: both drive formation of modified species in this hexapeptide.
- Wipe the stopper with a 70% alcohol wipe and let it dry before every access, and work on a clean, low-draught surface.
- Run the diluent down the inside wall of the vial rather than onto the powder, then swirl or roll; do not vortex or shake, because foaming and shear promote aggregation (Manning 2010).
- The sequence contains tryptophan, which photo-oxidises; keep the vial in its box or an opaque container (Manning 2010).
Sources
- Catalogue specification for GHRP-6, held in the product data for this site.
- Santana 2021, Journal of Pharmaceutical and Biomedical Analysis, PMID 33272786
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 2010. PMID 20143256
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 1999. PMID 10460913
- Meyer BK, Ni A, Hu B, Shi L. Antimicrobial preservative use in parenteral products: past and present. Journal of Pharmaceutical Sciences, 2007. PMID 17722087
Hexarelin2mgBacteriostatic water4 mg/ml at 0.5 ml
Solvent
No compound-specific solvent or solubility data is published for this material. Bacteriostatic water is the default for a lyophilised preparation.
Concentration options
2mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 0.5 ml | 4 mg/ml | 4,000 |
| 1 ml | 2 mg/ml | 2,000 |
| 2 ml | 1 mg/ml | 1,000 |
Volumes are concentration options, not a protocol. Do not exceed the nominal capacity of the vial.
Lyophilised storage
Sealed vial: -20°C for long-term storage, 2 to 8°C for up to a few months. Keep it dark and dry and let the vial reach room temperature before opening, so moisture does not condense on the powder.
Diluted storage
2 to 8°C, protected from light. If the preparation has to be kept longer, divide it into single-use aliquots and freeze them at -20°C, then thaw each aliquot once.
Stability data
No published stability data for this compound in either form. Store it as set out above and treat any time in solution as short.
Handling cautions
- Wipe the stopper with a 70% alcohol wipe and let it dry before every access, and work on a clean, low-draught surface.
- Run the diluent down the inside wall of the vial rather than onto the powder, then swirl or roll; do not vortex or shake, because foaming and shear promote aggregation (Manning 2010).
- The sequence contains tryptophan, which photo-oxidises; keep the vial in its box or an opaque container (Manning 2010).
Sources
- Catalogue specification for Hexarelin, held in the product data for this site.
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 2010. PMID 20143256
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 1999. PMID 10460913
- Meyer BK, Ni A, Hu B, Shi L. Antimicrobial preservative use in parenteral products: past and present. Journal of Pharmaceutical Sciences, 2007. PMID 17722087
Sermorelin2mg, 5mg, 10mgBacteriostatic water4 mg/ml at 0.5 ml
Solvent
No compound-specific solvent or solubility data is published for this material. Bacteriostatic water is the default for a lyophilised preparation.
Concentration options
2mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 0.5 ml | 4 mg/ml | 4,000 |
| 1 ml | 2 mg/ml | 2,000 |
| 2 ml | 1 mg/ml | 1,000 |
5mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 1 ml | 5 mg/ml | 5,000 |
| 2 ml | 2.5 mg/ml | 2,500 |
| 2.5 ml | 2 mg/ml | 2,000 |
10mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 1 ml | 10 mg/ml | 10,000 |
| 2 ml | 5 mg/ml | 5,000 |
| 2.5 ml | 4 mg/ml | 4,000 |
| 5 ml | 2 mg/ml | 2,000 |
Volumes are concentration options, not a protocol. Do not exceed the nominal capacity of the vial.
Lyophilised storage
Sealed vial: -20°C for long-term storage, 2 to 8°C for up to a few months. Keep it dark and dry and let the vial reach room temperature before opening, so moisture does not condense on the powder.
Diluted storage
2 to 8°C, protected from light. If the preparation has to be kept longer, divide it into single-use aliquots and freeze them at -20°C, then thaw each aliquot once.
Stability data
GRF(1-29)-NH2, the fragment sold as sermorelin, is most stable at pH 4 to 5. Below that, cleavage at the aspartic acid residue dominates; above it, deamidation of the asparagine residue takes over. (Bongers 1992, International Journal of Peptide and Protein Research, PMID 1428526)
Handling cautions
- Wipe the stopper with a 70% alcohol wipe and let it dry before every access, and work on a clean, low-draught surface.
- Run the diluent down the inside wall of the vial rather than onto the powder, then swirl or roll; do not vortex or shake, because foaming and shear promote aggregation (Manning 2010).
Sources
- Catalogue specification for Sermorelin, held in the product data for this site.
- Bongers 1992, International Journal of Peptide and Protein Research, PMID 1428526
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 2010. PMID 20143256
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 1999. PMID 10460913
- Meyer BK, Ni A, Hu B, Shi L. Antimicrobial preservative use in parenteral products: past and present. Journal of Pharmaceutical Sciences, 2007. PMID 17722087
IGF-1 LR31mg0.1 M acetic acid2 mg/ml at 0.5 ml
Solvent
The acidic stock is the standard laboratory handling for this protein family. For IGF-I in acetate buffer the documented loss routes were methionine oxidation and reducible dimer and trimer, and a histidine buffer held the protein together better (Germershaus 2013). No solvent study of the LR3 variant itself is published, so this is best practice applied from the parent molecule, not an LR3-specific finding.
Concentration options
1mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 0.5 ml | 2 mg/ml | 2,000 |
| 1 ml | 1 mg/ml | 1,000 |
| 2 ml | 0.5 mg/ml | 500 |
Keep the stock acidic. Neutralising it drives aggregation, which is why the stock is diluted into buffer rather than titrated to pH 7.
Volumes are concentration options, not a protocol. Do not exceed the nominal capacity of the vial.
Lyophilised storage
Sealed vial: -20°C for long-term storage, 2 to 8°C for up to a few months. Keep it dark and dry and let the vial reach room temperature before opening, so moisture does not condense on the powder.
Diluted storage
2 to 8°C, protected from light. If the preparation has to be kept longer, divide it into single-use aliquots and freeze them at -20°C, then thaw each aliquot once.
Stability data
No published shelf-life figure for this compound in aqueous solution. The research that does exist is printed below, labelled with how far it actually applies, and none of it is used here as a working time in solution: store it as set out above and treat any time in solution as short.
Related molecule only (IGF-I, not LR3): For IGF-I in acetate buffer, oxidation of the methionine residue and reducible dimer and trimer were the loss routes, and a histidine buffer held the protein together better. The LR3 variant sold here has no dataset of its own, so this is context for the acidic stock, not a shelf life. (Germershaus 2013, European Journal of Pharmaceutics and Biopharmaceutics, PMID 23958318)
Handling cautions
- Do not neutralise the stock: solubility and stability are both pH dependent for this protein.
- Adsorbs to some plastics; use low-binding tubes for aliquots.
- Wipe the stopper with a 70% alcohol wipe and let it dry before every access, and work on a clean, low-draught surface.
- Run the diluent down the inside wall of the vial rather than onto the powder, then swirl or roll; do not vortex or shake, because foaming and shear promote aggregation (Manning 2010).
Sources
- Catalogue specification for IGF-1 LR3, held in the product data for this site.
- Germershaus 2013, European Journal of Pharmaceutics and Biopharmaceutics, PMID 23958318 (IGF-I, not the LR3 variant)
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 2010. PMID 20143256
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 1999. PMID 10460913
Kisspeptin-1010mgBacteriostatic water10 mg/ml at 1 ml
Solvent
No compound-specific solvent or solubility data is published for this material. Bacteriostatic water is the default for a lyophilised preparation.
Concentration options
10mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 1 ml | 10 mg/ml | 10,000 |
| 2 ml | 5 mg/ml | 5,000 |
| 2.5 ml | 4 mg/ml | 4,000 |
| 5 ml | 2 mg/ml | 2,000 |
Volumes are concentration options, not a protocol. Do not exceed the nominal capacity of the vial.
Lyophilised storage
Sealed vial: -20°C for long-term storage, 2 to 8°C for up to a few months. Keep it dark and dry and let the vial reach room temperature before opening, so moisture does not condense on the powder.
Diluted storage
2 to 8°C, protected from light. If the preparation has to be kept longer, divide it into single-use aliquots and freeze them at -20°C, then thaw each aliquot once.
Stability data
No published shelf-life figure for this compound in aqueous solution. The research that does exist is printed below, labelled with how far it actually applies, and none of it is used here as a working time in solution: store it as set out above and treat any time in solution as short.
Same molecule, plasma matrix: Kisspeptin-10 incubated in rat plasma decomposed with an initial half-life of 6.8 minutes at 4 degrees, 2.9 at 25 and 1.7 at 37, losing the N-terminal tyrosine as its main product, and more than 90% was gone within 30 minutes. Plasma is an enzyme-rich matrix, so this bounds handling rather than giving a buffer shelf life. (Liu 2013, Journal of Chromatography B, PMID 23524040)
Handling cautions
- Half-life figures published for kisspeptin-10 come from rat plasma, not from an aqueous buffer stock, so they bound handling in that matrix and are not a time in solution; do not carry them over to a stock. Prepare the working dilution immediately before use and do not hold it across a session.
- Wipe the stopper with a 70% alcohol wipe and let it dry before every access, and work on a clean, low-draught surface.
- Run the diluent down the inside wall of the vial rather than onto the powder, then swirl or roll; do not vortex or shake, because foaming and shear promote aggregation (Manning 2010).
Sources
- Catalogue specification for Kisspeptin-10, held in the product data for this site.
- Liu 2013, Journal of Chromatography B, PMID 23524040 (same molecule, plasma matrix)
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 2010. PMID 20143256
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 1999. PMID 10460913
- Meyer BK, Ni A, Hu B, Shi L. Antimicrobial preservative use in parenteral products: past and present. Journal of Pharmaceutical Sciences, 2007. PMID 17722087
MGF2mgBacteriostatic water4 mg/ml at 0.5 ml
Solvent
No compound-specific solvent or solubility data is published for this material. Bacteriostatic water is the default for a lyophilised preparation.
Concentration options
2mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 0.5 ml | 4 mg/ml | 4,000 |
| 1 ml | 2 mg/ml | 2,000 |
| 2 ml | 1 mg/ml | 1,000 |
If the powder does not clear in water at neutral pH, 0.1 M acetic acid is the documented alternative. Record which solvent was used on the vial label, because the concentration arithmetic is the same but the solution is not interchangeable.
Volumes are concentration options, not a protocol. Do not exceed the nominal capacity of the vial.
Lyophilised storage
Sealed vial: -20°C for long-term storage, 2 to 8°C for up to a few months. Keep it dark and dry and let the vial reach room temperature before opening, so moisture does not condense on the powder.
Diluted storage
2 to 8°C, protected from light. If the preparation has to be kept longer, divide it into single-use aliquots and freeze them at -20°C, then thaw each aliquot once.
Stability data
No published stability data for this compound in either form. Store it as set out above and treat any time in solution as short.
Handling cautions
- Wipe the stopper with a 70% alcohol wipe and let it dry before every access, and work on a clean, low-draught surface.
- Run the diluent down the inside wall of the vial rather than onto the powder, then swirl or roll; do not vortex or shake, because foaming and shear promote aggregation (Manning 2010).
Sources
- Catalogue specification for MGF, held in the product data for this site.
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 2010. PMID 20143256
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 1999. PMID 10460913
- Meyer BK, Ni A, Hu B, Shi L. Antimicrobial preservative use in parenteral products: past and present. Journal of Pharmaceutical Sciences, 2007. PMID 17722087
PEG-MGF2mgBacteriostatic water4 mg/ml at 0.5 ml
Solvent
No compound-specific solvent or solubility data is published for this material. Bacteriostatic water is the default for a lyophilised preparation.
Concentration options
2mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 0.5 ml | 4 mg/ml | 4,000 |
| 1 ml | 2 mg/ml | 2,000 |
| 2 ml | 1 mg/ml | 1,000 |
PEGylation makes the powder slower to wet out. Add the diluent, leave it two to three minutes, then swirl; do not heat or sonicate.
Volumes are concentration options, not a protocol. Do not exceed the nominal capacity of the vial.
Lyophilised storage
Sealed vial: -20°C for long-term storage, 2 to 8°C for up to a few months. Keep it dark and dry and let the vial reach room temperature before opening, so moisture does not condense on the powder.
Diluted storage
2 to 8°C, protected from light. If the preparation has to be kept longer, divide it into single-use aliquots and freeze them at -20°C, then thaw each aliquot once.
Stability data
No published stability data for this compound in either form. Store it as set out above and treat any time in solution as short.
Handling cautions
- Wipe the stopper with a 70% alcohol wipe and let it dry before every access, and work on a clean, low-draught surface.
- Run the diluent down the inside wall of the vial rather than onto the powder, then swirl or roll; do not vortex or shake, because foaming and shear promote aggregation (Manning 2010).
Sources
- Catalogue specification for PEG-MGF, held in the product data for this site.
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 2010. PMID 20143256
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 1999. PMID 10460913
- Meyer BK, Ni A, Hu B, Shi L. Antimicrobial preservative use in parenteral products: past and present. Journal of Pharmaceutical Sciences, 2007. PMID 17722087
Longevity research
NAD+500mg, 1000mgSterile water50 mg/ml at 10 ml
Solvent
NAD+ is measured at 260 nm and 340 nm, where the benzyl alcohol in a preserved diluent absorbs (Meyer 2007), so a preservative-free sterile water stock is used instead. The free dinucleotide is hydrolytically labile, with a half-life measured in tens of hours at 37 degrees (McDonough 2025), so the stock is prepared fresh and kept cold.
Concentration options
500mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 10 ml | 50 mg/ml | 50,000 |
1000mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 10 ml | 100 mg/ml | 100,000 |
| 20 ml | 50 mg/ml | 50,000 |
Prepare the stock on the day of use and keep it on ice. A preserved multi-access vial is the wrong container here.
Volumes are concentration options, not a protocol. Do not exceed the nominal capacity of the vial.
Lyophilised storage
Sealed vial: -20°C for long-term storage, 2 to 8°C for up to a few months. Keep it dark and dry and let the vial reach room temperature before opening, so moisture does not condense on the powder.
Diluted storage
2 to 8°C, protected from light. If the preparation has to be kept longer, divide it into single-use aliquots and freeze them at -20°C, then thaw each aliquot once.
Stability data
Free NAD+ is hydrolytically unstable in aqueous solution, with a half-life of about 34 hours at 37 degrees; tethering the cofactor to silica is what extends it, which locates the fragility in the free dinucleotide rather than the buffer. (McDonough 2025, ACS Synthetic Biology, PMID 40468472)
Handling cautions
- Hydrolysis accelerates as pH rises; do not make the stock in an alkaline buffer.
- Prepare fresh, keep cold, protect from light, and discard the remainder rather than storing it.
- Wipe the stopper with a 70% alcohol wipe and let it dry before every access, and work on a clean, low-draught surface.
- Run the diluent down the inside wall of the vial rather than onto the powder, then swirl or roll; do not vortex or shake, because foaming and shear promote aggregation (Manning 2010).
Sources
- Catalogue specification for NAD+ (white to off-white lyophilised powder), held in the product data for this site.
- McDonough 2025, ACS Synthetic Biology, PMID 40468472
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 2010. PMID 20143256
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 1999. PMID 10460913
Epithalon10mgBacteriostatic water10 mg/ml at 1 ml
Solvent
No compound-specific solvent or solubility data is published for this material. Bacteriostatic water is the default for a lyophilised preparation.
Concentration options
10mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 1 ml | 10 mg/ml | 10,000 |
| 2 ml | 5 mg/ml | 5,000 |
| 2.5 ml | 4 mg/ml | 4,000 |
| 5 ml | 2 mg/ml | 2,000 |
Unverified supplier guidance limits aqueous storage of a stock to one day. Prepare it for the session rather than the week, and record the preparation time.
Volumes are concentration options, not a protocol. Do not exceed the nominal capacity of the vial.
Lyophilised storage
Sealed vial: -20°C for long-term storage, 2 to 8°C for up to a few months. Keep it dark and dry and let the vial reach room temperature before opening, so moisture does not condense on the powder.
Diluted storage
Prepared for the session: the quoted working life of a stock is one day, and no primary dataset was found to extend it. Keep it at 2 to 8°C and protected from light in the meantime.
Stability data
No published stability data for this compound in either form. Store it as set out above and treat any time in solution as short.
Handling cautions
- Wipe the stopper with a 70% alcohol wipe and let it dry before every access, and work on a clean, low-draught surface.
- Run the diluent down the inside wall of the vial rather than onto the powder, then swirl or roll; do not vortex or shake, because foaming and shear promote aggregation (Manning 2010).
Sources
- Catalogue specification for Epithalon, held in the product data for this site.
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 2010. PMID 20143256
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 1999. PMID 10460913
- Meyer BK, Ni A, Hu B, Shi L. Antimicrobial preservative use in parenteral products: past and present. Journal of Pharmaceutical Sciences, 2007. PMID 17722087
SS-3110mg, 50mgBacteriostatic water10 mg/ml at 1 ml
Solvent
No compound-specific solvent or solubility data is published for this material. Bacteriostatic water is the default for a lyophilised preparation.
Concentration options
10mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 1 ml | 10 mg/ml | 10,000 |
| 2 ml | 5 mg/ml | 5,000 |
| 2.5 ml | 4 mg/ml | 4,000 |
| 5 ml | 2 mg/ml | 2,000 |
50mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 5 ml | 10 mg/ml | 10,000 |
| 10 ml | 5 mg/ml | 5,000 |
Volumes are concentration options, not a protocol. Do not exceed the nominal capacity of the vial.
Lyophilised storage
Sealed vial: -20°C for long-term storage, 2 to 8°C for up to a few months. Keep it dark and dry and let the vial reach room temperature before opening, so moisture does not condense on the powder.
Diluted storage
2 to 8°C, protected from light. If the preparation has to be kept longer, divide it into single-use aliquots and freeze them at -20°C, then thaw each aliquot once.
Stability data
No published shelf-life figure for this compound in aqueous solution. The research that does exist is printed below, labelled with how far it actually applies, and none of it is used here as a working time in solution: store it as set out above and treat any time in solution as short.
Review statement, not a dataset: A review describes SS-31 as water-soluble, stable in solution and resistant to peptidases. No primary pH-rate or shelf-life study is cited for that statement, so the working window is treated as short. (Zhu 2022, Oxidative Medicine and Cellular Longevity, PMID 35707274)
Handling cautions
- Wipe the stopper with a 70% alcohol wipe and let it dry before every access, and work on a clean, low-draught surface.
- Run the diluent down the inside wall of the vial rather than onto the powder, then swirl or roll; do not vortex or shake, because foaming and shear promote aggregation (Manning 2010).
Sources
- Catalogue specification for SS-31, held in the product data for this site.
- Zhu 2022, Oxidative Medicine and Cellular Longevity, PMID 35707274 (review statement, not a dataset)
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 2010. PMID 20143256
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 1999. PMID 10460913
- Meyer BK, Ni A, Hu B, Shi L. Antimicrobial preservative use in parenteral products: past and present. Journal of Pharmaceutical Sciences, 2007. PMID 17722087
DSIP5mg, 10mgBacteriostatic water5 mg/ml at 1 ml
Solvent
No compound-specific solvent or solubility data is published for this material. Bacteriostatic water is the default for a lyophilised preparation.
Concentration options
5mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 1 ml | 5 mg/ml | 5,000 |
| 2 ml | 2.5 mg/ml | 2,500 |
| 2.5 ml | 2 mg/ml | 2,000 |
10mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 1 ml | 10 mg/ml | 10,000 |
| 2 ml | 5 mg/ml | 5,000 |
| 2.5 ml | 4 mg/ml | 4,000 |
| 5 ml | 2 mg/ml | 2,000 |
Volumes are concentration options, not a protocol. Do not exceed the nominal capacity of the vial.
Lyophilised storage
Sealed vial: -20°C for long-term storage, 2 to 8°C for up to a few months. Keep it dark and dry and let the vial reach room temperature before opening, so moisture does not condense on the powder.
Diluted storage
2 to 8°C, protected from light. If the preparation has to be kept longer, divide it into single-use aliquots and freeze them at -20°C, then thaw each aliquot once.
Stability data
DSIP was fairly stable across pH 4 to 9 buffers; the loss observed in that work came from enzymes, not from hydrolysis. (Chiang 1998, Drug Development and Industrial Pharmacy, PMID 9876605)
Handling cautions
- Wipe the stopper with a 70% alcohol wipe and let it dry before every access, and work on a clean, low-draught surface.
- Run the diluent down the inside wall of the vial rather than onto the powder, then swirl or roll; do not vortex or shake, because foaming and shear promote aggregation (Manning 2010).
- The sequence contains tryptophan, which photo-oxidises; keep the vial in its box or an opaque container (Manning 2010).
Sources
- Catalogue specification for DSIP, held in the product data for this site.
- Chiang 1998, Drug Development and Industrial Pharmacy, PMID 9876605
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 2010. PMID 20143256
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 1999. PMID 10460913
- Meyer BK, Ni A, Hu B, Shi L. Antimicrobial preservative use in parenteral products: past and present. Journal of Pharmaceutical Sciences, 2007. PMID 17722087
Thymosin Alpha-15mg, 10mgBacteriostatic water5 mg/ml at 1 ml
Solvent
No compound-specific solvent or solubility data is published for this material. Bacteriostatic water is the default for a lyophilised preparation.
Concentration options
5mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 1 ml | 5 mg/ml | 5,000 |
| 2 ml | 2.5 mg/ml | 2,500 |
| 2.5 ml | 2 mg/ml | 2,000 |
10mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 1 ml | 10 mg/ml | 10,000 |
| 2 ml | 5 mg/ml | 5,000 |
| 2.5 ml | 4 mg/ml | 4,000 |
| 5 ml | 2 mg/ml | 2,000 |
Volumes are concentration options, not a protocol. Do not exceed the nominal capacity of the vial.
Lyophilised storage
Sealed vial: -20°C for long-term storage, 2 to 8°C for up to a few months. Keep it dark and dry and let the vial reach room temperature before opening, so moisture does not condense on the powder.
Diluted storage
2 to 8°C, protected from light. If the preparation has to be kept longer, divide it into single-use aliquots and freeze them at -20°C, then thaw each aliquot once.
Stability data
No published stability data for this compound in either form. Store it as set out above and treat any time in solution as short.
Handling cautions
- Wipe the stopper with a 70% alcohol wipe and let it dry before every access, and work on a clean, low-draught surface.
- Run the diluent down the inside wall of the vial rather than onto the powder, then swirl or roll; do not vortex or shake, because foaming and shear promote aggregation (Manning 2010).
Sources
- Catalogue specification for Thymosin Alpha-1, held in the product data for this site.
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 2010. PMID 20143256
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 1999. PMID 10460913
- Meyer BK, Ni A, Hu B, Shi L. Antimicrobial preservative use in parenteral products: past and present. Journal of Pharmaceutical Sciences, 2007. PMID 17722087
Thymalin10mgBacteriostatic water10 mg/ml at 1 ml
Solvent
No compound-specific solvent or solubility data is published for this material. Bacteriostatic water is the default for a lyophilised preparation.
Concentration options
10mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 1 ml | 10 mg/ml | 10,000 |
| 2 ml | 5 mg/ml | 5,000 |
| 2.5 ml | 4 mg/ml | 4,000 |
| 5 ml | 2 mg/ml | 2,000 |
Volumes are concentration options, not a protocol. Do not exceed the nominal capacity of the vial.
Lyophilised storage
Sealed vial: -20°C for long-term storage, 2 to 8°C for up to a few months. Keep it dark and dry and let the vial reach room temperature before opening, so moisture does not condense on the powder.
Diluted storage
2 to 8°C, protected from light. If the preparation has to be kept longer, divide it into single-use aliquots and freeze them at -20°C, then thaw each aliquot once.
Stability data
No published stability data for this compound in either form. Store it as set out above and treat any time in solution as short.
Handling cautions
- Wipe the stopper with a 70% alcohol wipe and let it dry before every access, and work on a clean, low-draught surface.
- Run the diluent down the inside wall of the vial rather than onto the powder, then swirl or roll; do not vortex or shake, because foaming and shear promote aggregation (Manning 2010).
Sources
- Catalogue specification for Thymalin, held in the product data for this site.
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 2010. PMID 20143256
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 1999. PMID 10460913
- Meyer BK, Ni A, Hu B, Shi L. Antimicrobial preservative use in parenteral products: past and present. Journal of Pharmaceutical Sciences, 2007. PMID 17722087
Semax10mg, 5mgBacteriostatic water10 mg/ml at 1 ml
Solvent
No compound-specific solvent or solubility data is published for this material. Bacteriostatic water is the default for a lyophilised preparation.
Concentration options
10mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 1 ml | 10 mg/ml | 10,000 |
| 2 ml | 5 mg/ml | 5,000 |
| 2.5 ml | 4 mg/ml | 4,000 |
| 5 ml | 2 mg/ml | 2,000 |
5mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 1 ml | 5 mg/ml | 5,000 |
| 2 ml | 2.5 mg/ml | 2,500 |
| 2.5 ml | 2 mg/ml | 2,000 |
Unverified supplier guidance limits aqueous storage of a stock to one day, so a stock is prepared for the session rather than the week.
Volumes are concentration options, not a protocol. Do not exceed the nominal capacity of the vial.
Lyophilised storage
Sealed vial: -20°C for long-term storage, 2 to 8°C for up to a few months. Keep it dark and dry and let the vial reach room temperature before opening, so moisture does not condense on the powder.
Diluted storage
Prepared for the session: the quoted working life of a stock is one day, and no primary dataset was found to extend it. Keep it at 2 to 8°C and protected from light in the meantime.
Stability data
No published stability data for this compound in either form. Store it as set out above and treat any time in solution as short.
Handling cautions
- Wipe the stopper with a 70% alcohol wipe and let it dry before every access, and work on a clean, low-draught surface.
- Run the diluent down the inside wall of the vial rather than onto the powder, then swirl or roll; do not vortex or shake, because foaming and shear promote aggregation (Manning 2010).
- The sequence contains methionine, the usual first site of oxidation; keep the solution cold, dark and with minimal headspace (Manning 2010).
Sources
- Catalogue specification for Semax, held in the product data for this site.
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 2010. PMID 20143256
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 1999. PMID 10460913
- Meyer BK, Ni A, Hu B, Shi L. Antimicrobial preservative use in parenteral products: past and present. Journal of Pharmaceutical Sciences, 2007. PMID 17722087
Selank10mg, 5mgBacteriostatic water10 mg/ml at 1 ml
Solvent
No compound-specific solvent or solubility data is published for this material. Bacteriostatic water is the default for a lyophilised preparation.
Concentration options
10mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 1 ml | 10 mg/ml | 10,000 |
| 2 ml | 5 mg/ml | 5,000 |
| 2.5 ml | 4 mg/ml | 4,000 |
| 5 ml | 2 mg/ml | 2,000 |
5mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 1 ml | 5 mg/ml | 5,000 |
| 2 ml | 2.5 mg/ml | 2,500 |
| 2.5 ml | 2 mg/ml | 2,000 |
Unverified supplier guidance limits aqueous storage of a stock to one day, so a stock is prepared for the session rather than the week.
Volumes are concentration options, not a protocol. Do not exceed the nominal capacity of the vial.
Lyophilised storage
Sealed vial: -20°C for long-term storage, 2 to 8°C for up to a few months. Keep it dark and dry and let the vial reach room temperature before opening, so moisture does not condense on the powder.
Diluted storage
Prepared for the session: the quoted working life of a stock is one day, and no primary dataset was found to extend it. Keep it at 2 to 8°C and protected from light in the meantime.
Stability data
No published stability data for this compound in either form. Store it as set out above and treat any time in solution as short.
Handling cautions
- Wipe the stopper with a 70% alcohol wipe and let it dry before every access, and work on a clean, low-draught surface.
- Run the diluent down the inside wall of the vial rather than onto the powder, then swirl or roll; do not vortex or shake, because foaming and shear promote aggregation (Manning 2010).
Sources
- Catalogue specification for Selank, held in the product data for this site.
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 2010. PMID 20143256
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 1999. PMID 10460913
- Meyer BK, Ni A, Hu B, Shi L. Antimicrobial preservative use in parenteral products: past and present. Journal of Pharmaceutical Sciences, 2007. PMID 17722087
Adamax5mgDMSOpre-dissolve, no aqueous stock
Solvent
No aqueous solubility, stability or solvent dataset is published for adamax, and the only handling note available is an unverified supplier statement that it dissolves in DMSO. The reference therefore offers no aqueous stock and no concentration table for it.
Concentration options
Pre-dissolve in the minimum volume of DMSO only if you have your own solubility data for the batch, dilute an aliquot into buffer, and record the final DMSO percentage, because a co-solvent changes the assay.
The volume table is withheld for this compound: no validated aqueous stock exists, so any mg/ml figure here would be arithmetic without a basis.
Lyophilised storage
Sealed vial: -20°C for long-term storage, 2 to 8°C for up to a few months. Keep it dark and dry and let the vial reach room temperature before opening, so moisture does not condense on the powder.
Diluted storage
2 to 8°C, protected from light. If the preparation has to be kept longer, divide it into single-use aliquots and freeze them at -20°C, then thaw each aliquot once.
Stability data
No published stability data for this compound in either form. Store it as set out above and treat any time in solution as short.
Handling cautions
- Unverified handling: no primary source covers adamax, so treat every step as provisional and record what was done.
- Wipe the stopper with a 70% alcohol wipe and let it dry before every access, and work on a clean, low-draught surface.
- Run the diluent down the inside wall of the vial rather than onto the powder, then swirl or roll; do not vortex or shake, because foaming and shear promote aggregation (Manning 2010).
Sources
- Catalogue specification for Adamax, held in the product data for this site.
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 2010. PMID 20143256
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 1999. PMID 10460913
Glutathione1500mgSterile water150 mg/ml at 10 ml
Solvent
Reduced glutathione oxidises to the disulfide dimer, and forced-degradation work on glutathione formulations shows oxidation is the dominant loss route in aerated solution (Tsiasioti 2020). A preservative-free sterile water stock, made fresh in single-use aliquots, keeps the preparation simple and the loss visible.
Concentration options
1500mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 10 ml | 150 mg/ml | 150,000 |
| 20 ml | 75 mg/ml | 75,000 |
Volumes are concentration options, not a protocol. Do not exceed the nominal capacity of the vial.
Lyophilised storage
Sealed vial: -20°C for long-term storage, 2 to 8°C for up to a few months. Keep it dark and dry and let the vial reach room temperature before opening, so moisture does not condense on the powder.
Diluted storage
2 to 8°C, protected from light. If the preparation has to be kept longer, divide it into single-use aliquots and freeze them at -20°C, then thaw each aliquot once.
Stability data
Reduced glutathione oxidises to the disulfide in aerated solution, and 3% peroxide drives more than 95% of it across in three hours; the reaction follows pseudo-first order kinetics. (Tsiasioti 2020, Separations, doi:10.3390/separations7010016)
Handling cautions
- Oxidation to the disulfide is the main loss route; keep the solution cold, minimise headspace and prepare close to use.
- Some colorimetric thiol assays are sensitive to the age of the solution; run a fresh blank with each preparation.
- Wipe the stopper with a 70% alcohol wipe and let it dry before every access, and work on a clean, low-draught surface.
- Run the diluent down the inside wall of the vial rather than onto the powder, then swirl or roll; do not vortex or shake, because foaming and shear promote aggregation (Manning 2010).
Sources
- Catalogue specification for Glutathione, held in the product data for this site.
- Tsiasioti 2020, Separations, doi:10.3390/separations7010016
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 2010. PMID 20143256
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 1999. PMID 10460913
Oxytocin5mgBacteriostatic water5 mg/ml at 1 ml
Solvent
No compound-specific solvent or solubility data is published for this material. Bacteriostatic water is the default for a lyophilised preparation.
Concentration options
5mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 1 ml | 5 mg/ml | 5,000 |
| 2 ml | 2.5 mg/ml | 2,500 |
| 2.5 ml | 2 mg/ml | 2,000 |
Volumes are concentration options, not a protocol. Do not exceed the nominal capacity of the vial.
Lyophilised storage
Sealed vial: -20°C for long-term storage, 2 to 8°C for up to a few months. Keep it dark and dry and let the vial reach room temperature before opening, so moisture does not condense on the powder.
Diluted storage
2 to 8°C, protected from light. If the preparation has to be kept longer, divide it into single-use aliquots and freeze them at -20°C, then thaw each aliquot once.
Stability data
Aqueous oxytocin was stabilised by 5 to 10 mM citrate buffer at pH 4.5 combined with at least 2 mM of a divalent metal ion; acetate buffer with the same ions did not give the same improvement. (Avanti 2011, The AAPS Journal, PMID 21448747)
Handling cautions
- Light-sensitive in solution; keep it dark and cold.
- Supplied as the acetate salt; the counter-ion is not removed by reconstitution.
- Wipe the stopper with a 70% alcohol wipe and let it dry before every access, and work on a clean, low-draught surface.
- Run the diluent down the inside wall of the vial rather than onto the powder, then swirl or roll; do not vortex or shake, because foaming and shear promote aggregation (Manning 2010).
Sources
- Catalogue specification for Oxytocin, held in the product data for this site.
- Avanti 2011, The AAPS Journal, PMID 21448747
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 2010. PMID 20143256
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 1999. PMID 10460913
- Meyer BK, Ni A, Hu B, Shi L. Antimicrobial preservative use in parenteral products: past and present. Journal of Pharmaceutical Sciences, 2007. PMID 17722087
Pinealon10mgBacteriostatic water10 mg/ml at 1 ml
Solvent
No compound-specific solvent or solubility data is published for this material. Bacteriostatic water is the default for a lyophilised preparation.
Concentration options
10mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 1 ml | 10 mg/ml | 10,000 |
| 2 ml | 5 mg/ml | 5,000 |
| 2.5 ml | 4 mg/ml | 4,000 |
| 5 ml | 2 mg/ml | 2,000 |
Volumes are concentration options, not a protocol. Do not exceed the nominal capacity of the vial.
Lyophilised storage
Sealed vial: -20°C for long-term storage, 2 to 8°C for up to a few months. Keep it dark and dry and let the vial reach room temperature before opening, so moisture does not condense on the powder.
Diluted storage
2 to 8°C, protected from light. If the preparation has to be kept longer, divide it into single-use aliquots and freeze them at -20°C, then thaw each aliquot once.
Stability data
No published stability data for this compound in either form. Store it as set out above and treat any time in solution as short.
Handling cautions
- Wipe the stopper with a 70% alcohol wipe and let it dry before every access, and work on a clean, low-draught surface.
- Run the diluent down the inside wall of the vial rather than onto the powder, then swirl or roll; do not vortex or shake, because foaming and shear promote aggregation (Manning 2010).
Sources
- Catalogue specification for Pinealon, held in the product data for this site.
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 2010. PMID 20143256
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 1999. PMID 10460913
- Meyer BK, Ni A, Hu B, Shi L. Antimicrobial preservative use in parenteral products: past and present. Journal of Pharmaceutical Sciences, 2007. PMID 17722087
Pigmentation research
Melanotan 210mgDMSOpre-dissolve, no aqueous stock
Solvent
No primary aqueous solubility dataset could be found for this peptide, so the reference does not print an aqueous stock. Published work on MT-II measures its degradation in aqueous solution (Ugwu 1994), which shows it dissolves at low concentration but gives no workable stock figure. It is therefore handled as a DMSO pre-dissolve: dissolve the powder in the minimum volume of DMSO that clears it, then dilute an aliquot of that concentrate into the buffer the experiment needs.
Concentration options
There is no aqueous concentration table for this compound. A figure of about 0.2 mg/ml is quoted in supplier material but could not be traced to a primary study, so it is unverified: test a small quantity before committing the vial, record what actually dissolved, and record the final DMSO percentage, which changes the assay. The aqueous degradation kinetics themselves are published (Ugwu 1994).
The volume table is withheld for this compound: no validated aqueous stock exists, so any mg/ml figure here would be arithmetic without a basis.
Lyophilised storage
Sealed vial: -20°C for long-term storage, 2 to 8°C for up to a few months. Keep it dark and dry and let the vial reach room temperature before opening, so moisture does not condense on the powder.
Diluted storage
2 to 8°C, protected from light. If the preparation has to be kept longer, divide it into single-use aliquots and freeze them at -20°C, then thaw each aliquot once.
Stability data
Degradation of MT-II in aqueous solution follows apparent first-order kinetics, and the pH-rate profile puts maximum stability at about pH 5. Away from that pH the loss is faster, so the working pH is a deliberate choice rather than a default. (Ugwu 1994, International Journal of Pharmaceutics, doi:10.1016/0378-5173(94)90055-8)
Handling cautions
- Light-sensitive in solution; store in the dark and wrap the vial if it is kept on the bench.
- Keep the solution near the reported pH of maximum stability rather than assuming neutral is safest (Ugwu 1994).
- DMSO freezes at about 18.5°C: keep the concentrate at room temperature, not in the fridge.
- Wipe the stopper with a 70% alcohol wipe and let it dry before every access, and work on a clean, low-draught surface.
- Run the diluent down the inside wall of the vial rather than onto the powder, then swirl or roll; do not vortex or shake, because foaming and shear promote aggregation (Manning 2010).
Sources
- Catalogue specification for Melanotan 2, held in the product data for this site.
- Ugwu 1994, International Journal of Pharmaceutics, doi:10.1016/0378-5173(94)90055-8 (aqueous degradation kinetics of MT-II)
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 2010. PMID 20143256
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 1999. PMID 10460913
Melanotan 110mgBacteriostatic water10 mg/ml at 1 ml
Solvent
No compound-specific solvent or solubility data is published for this material. Bacteriostatic water is the default for a lyophilised preparation.
Concentration options
10mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 1 ml | 10 mg/ml | 10,000 |
| 2 ml | 5 mg/ml | 5,000 |
| 2.5 ml | 4 mg/ml | 4,000 |
| 5 ml | 2 mg/ml | 2,000 |
Volumes are concentration options, not a protocol. Do not exceed the nominal capacity of the vial.
Lyophilised storage
Sealed vial: -20°C for long-term storage, 2 to 8°C for up to a few months. Keep it dark and dry and let the vial reach room temperature before opening, so moisture does not condense on the powder.
Diluted storage
2 to 8°C, protected from light. If the preparation has to be kept longer, divide it into single-use aliquots and freeze them at -20°C, then thaw each aliquot once.
Stability data
No published shelf-life figure for this compound in aqueous solution. The research that does exist is printed below, labelled with how far it actually applies, and none of it is used here as a working time in solution: store it as set out above and treat any time in solution as short.
Same molecule, no shelf-life figure: A dedicated preformulation study measured the solution stability and partitioning of MT-I, so its degradation in aqueous solution was characterised, but the published record does not give a shelf life that can be quoted here. No numeric stability claim is made. (Surendran 1996, International Journal of Pharmaceutics, doi:10.1016/0378-5173(95)04394-2)
Handling cautions
- Light-sensitive in solution; store in the dark and wrap the vial if it is kept on the bench.
- Wipe the stopper with a 70% alcohol wipe and let it dry before every access, and work on a clean, low-draught surface.
- Run the diluent down the inside wall of the vial rather than onto the powder, then swirl or roll; do not vortex or shake, because foaming and shear promote aggregation (Manning 2010).
Sources
- Catalogue specification for Melanotan 1, held in the product data for this site.
- Surendran 1996, International Journal of Pharmaceutics, doi:10.1016/0378-5173(95)04394-2 (same molecule, no shelf-life figure)
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 2010. PMID 20143256
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 1999. PMID 10460913
- Meyer BK, Ni A, Hu B, Shi L. Antimicrobial preservative use in parenteral products: past and present. Journal of Pharmaceutical Sciences, 2007. PMID 17722087
PT-14110mgBacteriostatic water10 mg/ml at 1 ml
Solvent
No compound-specific solvent or solubility data is published for this material. Bacteriostatic water is the default for a lyophilised preparation.
Concentration options
10mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 1 ml | 10 mg/ml | 10,000 |
| 2 ml | 5 mg/ml | 5,000 |
| 2.5 ml | 4 mg/ml | 4,000 |
| 5 ml | 2 mg/ml | 2,000 |
Volumes are concentration options, not a protocol. Do not exceed the nominal capacity of the vial.
Lyophilised storage
Sealed vial: -20°C for long-term storage, 2 to 8°C for up to a few months. Keep it dark and dry and let the vial reach room temperature before opening, so moisture does not condense on the powder.
Diluted storage
2 to 8°C, protected from light. If the preparation has to be kept longer, divide it into single-use aliquots and freeze them at -20°C, then thaw each aliquot once.
Stability data
Bremelanotide degrades less under acidic than under basic conditions and is markedly susceptible to oxidation; epimerisation is the other route the forced-degradation work resolves. (Yuvaraaj 2026, Analytical Methods, PMID 42485063)
Handling cautions
- Wipe the stopper with a 70% alcohol wipe and let it dry before every access, and work on a clean, low-draught surface.
- Run the diluent down the inside wall of the vial rather than onto the powder, then swirl or roll; do not vortex or shake, because foaming and shear promote aggregation (Manning 2010).
Sources
- Catalogue specification for PT-141, held in the product data for this site.
- Yuvaraaj 2026, Analytical Methods, PMID 42485063
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 2010. PMID 20143256
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 1999. PMID 10460913
- Meyer BK, Ni A, Hu B, Shi L. Antimicrobial preservative use in parenteral products: past and present. Journal of Pharmaceutical Sciences, 2007. PMID 17722087
Peptide blends
GLOW70mgBacteriostatic water14 mg/ml at 5 ml
Solvent
Catalogue specification: pale blue lyophilised powder (from the ghk-cu). No compound-specific solvent or solubility data is published for this material. Bacteriostatic water is the default for a lyophilised preparation.
Concentration options
70mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 5 ml | 14 mg/ml | 14,000 |
| 10 ml | 7 mg/ml | 7,000 |
The table gives total blend mass per ml. Per-component concentration is the component mass on the label divided by the same volume, so 70 mg in 5 ml is 14 mg/ml of total peptide and 10 mg/ml of GHK-Cu.
Volumes are concentration options, not a protocol. Do not exceed the nominal capacity of the vial.
Lyophilised storage
Sealed vial: -20°C for long-term storage, 2 to 8°C for up to a few months. Keep it dark and dry and let the vial reach room temperature before opening, so moisture does not condense on the powder.
Diluted storage
2 to 8°C, protected from light. If the preparation has to be kept longer, divide it into single-use aliquots and freeze them at -20°C, then thaw each aliquot once.
Stability data
No published stability data for this compound in either form. Store it as set out above and treat any time in solution as short.
Handling cautions
- Co-lyophilised blend: the components wet out at different rates. Swirl until the last of the cake has gone; do not filter or try to separate the components.
- The blue colour comes from GHK-Cu and is expected.
- Wipe the stopper with a 70% alcohol wipe and let it dry before every access, and work on a clean, low-draught surface.
- Run the diluent down the inside wall of the vial rather than onto the powder, then swirl or roll; do not vortex or shake, because foaming and shear promote aggregation (Manning 2010).
Sources
- Catalogue specification for GLOW (composition GHK-Cu 50mg, BPC-157 10mg, TB-500 10mg; pale blue lyophilised powder (from the ghk-cu)), held in the product data for this site.
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 2010. PMID 20143256
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 1999. PMID 10460913
- Meyer BK, Ni A, Hu B, Shi L. Antimicrobial preservative use in parenteral products: past and present. Journal of Pharmaceutical Sciences, 2007. PMID 17722087
KLOW80mgBacteriostatic water16 mg/ml at 5 ml
Solvent
Catalogue specification: pale blue lyophilised powder (from the ghk-cu). No compound-specific solvent or solubility data is published for this material. Bacteriostatic water is the default for a lyophilised preparation.
Concentration options
80mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 5 ml | 16 mg/ml | 16,000 |
| 10 ml | 8 mg/ml | 8,000 |
The table gives total blend mass per ml. Per-component concentration is the component mass on the label divided by the same volume.
Volumes are concentration options, not a protocol. Do not exceed the nominal capacity of the vial.
Lyophilised storage
Sealed vial: -20°C for long-term storage, 2 to 8°C for up to a few months. Keep it dark and dry and let the vial reach room temperature before opening, so moisture does not condense on the powder.
Diluted storage
2 to 8°C, protected from light. If the preparation has to be kept longer, divide it into single-use aliquots and freeze them at -20°C, then thaw each aliquot once.
Stability data
No published stability data for this compound in either form. Store it as set out above and treat any time in solution as short.
Handling cautions
- Co-lyophilised blend: swirl until fully dissolved, and do not filter it.
- The blue colour comes from GHK-Cu and is expected.
- Wipe the stopper with a 70% alcohol wipe and let it dry before every access, and work on a clean, low-draught surface.
- Run the diluent down the inside wall of the vial rather than onto the powder, then swirl or roll; do not vortex or shake, because foaming and shear promote aggregation (Manning 2010).
Sources
- Catalogue specification for KLOW (composition GHK-Cu 50mg, BPC-157 10mg, TB-500 10mg, KPV 10mg; pale blue lyophilised powder (from the ghk-cu)), held in the product data for this site.
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 2010. PMID 20143256
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 1999. PMID 10460913
- Meyer BK, Ni A, Hu B, Shi L. Antimicrobial preservative use in parenteral products: past and present. Journal of Pharmaceutical Sciences, 2007. PMID 17722087
Wolverine Stack5+5mg, 10+10mgBacteriostatic water10 mg/ml at 1 ml
Solvent
No compound-specific solvent or solubility data is published for this material. Bacteriostatic water is the default for a lyophilised preparation.
Concentration options
5+5mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 1 ml | 10 mg/ml | 10,000 |
| 2 ml | 5 mg/ml | 5,000 |
| 2.5 ml | 4 mg/ml | 4,000 |
| 5 ml | 2 mg/ml | 2,000 |
10+10mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 2 ml | 10 mg/ml | 10,000 |
| 5 ml | 4 mg/ml | 4,000 |
The table gives total blend mass per ml. Each component is half the stated total, so 10 mg total in 2 ml is 5 mg/ml of BPC-157 and 5 mg/ml of TB-500.
Volumes are concentration options, not a protocol. Do not exceed the nominal capacity of the vial.
Lyophilised storage
Sealed vial: -20°C for long-term storage, 2 to 8°C for up to a few months. Keep it dark and dry and let the vial reach room temperature before opening, so moisture does not condense on the powder.
Diluted storage
2 to 8°C, protected from light. If the preparation has to be kept longer, divide it into single-use aliquots and freeze them at -20°C, then thaw each aliquot once.
Stability data
No published stability data for this compound in either form. Store it as set out above and treat any time in solution as short.
Handling cautions
- Co-lyophilised blend: do not separate or filter; record the total mass not the component masses.
- Wipe the stopper with a 70% alcohol wipe and let it dry before every access, and work on a clean, low-draught surface.
- Run the diluent down the inside wall of the vial rather than onto the powder, then swirl or roll; do not vortex or shake, because foaming and shear promote aggregation (Manning 2010).
Sources
- Catalogue specification for Wolverine Stack (composition BPC-157 5mg, TB-500 5mg), held in the product data for this site.
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 2010. PMID 20143256
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 1999. PMID 10460913
- Meyer BK, Ni A, Hu B, Shi L. Antimicrobial preservative use in parenteral products: past and present. Journal of Pharmaceutical Sciences, 2007. PMID 17722087
Hulk Stack20mgBacteriostatic water10 mg/ml at 2 ml
Solvent
No compound-specific solvent or solubility data is published for this material. Bacteriostatic water is the default for a lyophilised preparation.
Concentration options
20mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 2 ml | 10 mg/ml | 10,000 |
| 5 ml | 4 mg/ml | 4,000 |
The table gives total blend mass per ml. Per-component concentration is the component mass on the label divided by the same volume.
Volumes are concentration options, not a protocol. Do not exceed the nominal capacity of the vial.
Lyophilised storage
Sealed vial: -20°C for long-term storage, 2 to 8°C for up to a few months. Keep it dark and dry and let the vial reach room temperature before opening, so moisture does not condense on the powder.
Diluted storage
2 to 8°C, protected from light. If the preparation has to be kept longer, divide it into single-use aliquots and freeze them at -20°C, then thaw each aliquot once.
Stability data
No published stability data for this compound in either form. Store it as set out above and treat any time in solution as short.
Handling cautions
- Co-lyophilised blend: do not separate or filter; record the total mass not the component masses.
- Wipe the stopper with a 70% alcohol wipe and let it dry before every access, and work on a clean, low-draught surface.
- Run the diluent down the inside wall of the vial rather than onto the powder, then swirl or roll; do not vortex or shake, because foaming and shear promote aggregation (Manning 2010).
Sources
- Catalogue specification for Hulk Stack (composition CJC-1295 DAC, Ipamorelin), held in the product data for this site.
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 2010. PMID 20143256
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 1999. PMID 10460913
- Meyer BK, Ni A, Hu B, Shi L. Antimicrobial preservative use in parenteral products: past and present. Journal of Pharmaceutical Sciences, 2007. PMID 17722087
CJC-1295 + Ipamorelin5+5mgBacteriostatic water10 mg/ml at 1 ml
Solvent
No compound-specific solvent or solubility data is published for this material. Bacteriostatic water is the default for a lyophilised preparation.
Concentration options
5+5mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 1 ml | 10 mg/ml | 10,000 |
| 2 ml | 5 mg/ml | 5,000 |
| 2.5 ml | 4 mg/ml | 4,000 |
| 5 ml | 2 mg/ml | 2,000 |
The table gives total blend mass per ml. With a 5 + 5 mg vial, 2 ml gives 5 mg/ml in total, which is 2.5 mg/ml of each component.
Volumes are concentration options, not a protocol. Do not exceed the nominal capacity of the vial.
Lyophilised storage
Sealed vial: -20°C for long-term storage, 2 to 8°C for up to a few months. Keep it dark and dry and let the vial reach room temperature before opening, so moisture does not condense on the powder.
Diluted storage
2 to 8°C, protected from light. If the preparation has to be kept longer, divide it into single-use aliquots and freeze them at -20°C, then thaw each aliquot once.
Stability data
No published stability data for this compound in either form. Store it as set out above and treat any time in solution as short.
Handling cautions
- Co-lyophilised blend: do not separate or filter; record the total mass not the component masses.
- Wipe the stopper with a 70% alcohol wipe and let it dry before every access, and work on a clean, low-draught surface.
- Run the diluent down the inside wall of the vial rather than onto the powder, then swirl or roll; do not vortex or shake, because foaming and shear promote aggregation (Manning 2010).
Sources
- Catalogue specification for CJC-1295 + Ipamorelin (composition CJC-1295 5mg, Ipamorelin 5mg), held in the product data for this site.
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 2010. PMID 20143256
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 1999. PMID 10460913
- Meyer BK, Ni A, Hu B, Shi L. Antimicrobial preservative use in parenteral products: past and present. Journal of Pharmaceutical Sciences, 2007. PMID 17722087
Selank + Semax10+10mgBacteriostatic water10 mg/ml at 2 ml
Solvent
No compound-specific solvent or solubility data is published for this material. Bacteriostatic water is the default for a lyophilised preparation.
Concentration options
10+10mg vial
| Diluent | Concentration | µg per ml |
|---|---|---|
| 2 ml | 10 mg/ml | 10,000 |
| 5 ml | 4 mg/ml | 4,000 |
The table gives total blend mass per ml. With a 10 + 10 mg vial, 4 ml gives 5 mg/ml in total, which is 2.5 mg/ml of each component.
Volumes are concentration options, not a protocol. Do not exceed the nominal capacity of the vial.
Lyophilised storage
Sealed vial: -20°C for long-term storage, 2 to 8°C for up to a few months. Keep it dark and dry and let the vial reach room temperature before opening, so moisture does not condense on the powder.
Diluted storage
2 to 8°C, protected from light. If the preparation has to be kept longer, divide it into single-use aliquots and freeze them at -20°C, then thaw each aliquot once.
Stability data
No published stability data for this compound in either form. Store it as set out above and treat any time in solution as short.
Handling cautions
- Co-lyophilised blend: do not separate or filter; record the total mass not the component masses.
- Wipe the stopper with a 70% alcohol wipe and let it dry before every access, and work on a clean, low-draught surface.
- Run the diluent down the inside wall of the vial rather than onto the powder, then swirl or roll; do not vortex or shake, because foaming and shear promote aggregation (Manning 2010).
Sources
- Catalogue specification for Selank + Semax (composition Selank 10mg, Semax 10mg), held in the product data for this site.
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 2010. PMID 20143256
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 1999. PMID 10460913
- Meyer BK, Ni A, Hu B, Shi L. Antimicrobial preservative use in parenteral products: past and present. Journal of Pharmaceutical Sciences, 2007. PMID 17722087
Lab supplies
Bacteriostatic Water10mlBacteriostatic water
Solvent
This item is the diluent, not a lyophilised powder. It is supplied as a sterile solution containing 0.9% benzyl alcohol and is used to reconstitute other vials in the catalogue.
Concentration options
Volumes are concentration options, not a protocol. Do not exceed the nominal capacity of the vial.
Lyophilised storage
Store the unopened vial at 2 to 8°C; do not freeze.
Diluted storage
2 to 8°C, protected from light. If the preparation has to be kept longer, divide it into single-use aliquots and freeze them at -20°C, then thaw each aliquot once.
Stability data
Benzyl alcohol at 0.9% is a recognised antimicrobial preservative for multi-dose parenteral preparations, which is the basis for its use in a multi-access laboratory vial. (Meyer 2007 (PMID 17722087))
Handling cautions
- Do not freeze: the vial is a solution and freezing serves no purpose.
- Swipe the stopper before each access and keep the vial at 2 to 8°C once opened; a multi-access vial has a limited working life after first use.
- Not for spectrophotometry at or near 260 nm, where benzyl alcohol absorbs.
Sources
- Catalogue specification for Bacteriostatic Water (sterile solution; clear, colourless liquid), held in the product data for this site.
- Meyer 2007 (PMID 17722087)
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 2010. PMID 20143256
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 1999. PMID 10460913
- Meyer BK, Ni A, Hu B, Shi L. Antimicrobial preservative use in parenteral products: past and present. Journal of Pharmaceutical Sciences, 2007. PMID 17722087
Work it out for a specific vial
The calculator takes the vial mass and the diluent volume and returns mg/ml, µg/ml, the molar concentration where a molecular weight is published, and the volume of stock that contains a target mass.
Open the reconstitution calculatorReference FAQs
How much diluent does a 10mg vial need?+
Any volume you choose: the amount of peptide does not change, only the concentration. 10mg in 1ml is 10mg/ml, in 2ml is 5mg/ml, in 5ml is 2mg/ml. Pick the concentration your assay needs and check the vial's nominal capacity before you draw anything up.
Should I use bacteriostatic water or sterile water?+
Bacteriostatic water (sterile water with 0.9% benzyl alcohol) is the default for a vial you will open more than once, because the benzyl alcohol limits microbial growth. Sterile water without a preservative is used where a preservative would interfere with an assay, for example spectrophotometry at 260 nm, and the stock is then single-use.
Why does the reference say some compounds need dilute acetic acid?+
A few peptides are poorly soluble or poorly stable at neutral pH, and a 0.1 M acetic acid stock keeps them in solution. The stock stays acidic; it is diluted into buffer on the day of the experiment rather than neutralised.
Why is DMSO listed for some compounds?+
Because no aqueous stock can be justified for them, so the water-only tables would be arithmetic without a basis. The powder is dissolved in the minimum volume of DMSO and an aliquot is diluted into buffer. DMSO freezes at about 18.5°C, carries solutes through many plastics and changes most assays, so the final DMSO percentage is recorded.
Why do some compounds say there is no published stability data?+
Because no published shelf-life figure applies to that peptide in either form. Rather than print a shelf life that no paper supports, the reference says so and falls back to the general handling guidance: dry storage at -20°C, solutions at 2 to 8°C, protected from light, aliquoted and thawed once. Where a study does exist but gives no shelf-life figure, covers a different molecule or covers a non-aqueous matrix, it is shown as a labelled note, not as a shelf life.
Does a blend have a different concentration from a single peptide?+
Yes, in one respect: the stated vial mass is the total of all components. A 10mg blend in 2ml is 5mg/ml of total peptide, which is 2.5mg/ml of each component if the blend is an equal mix. The per-component mass is printed on the label.
Handling steps, aliquoting and labelling are covered in the reconstitution guide. Storage across both forms is covered in the storage guide. Batch documents are on the lab reports page, and the guide to reading a certificate of analysis explains what each field means.